Trial intelligence / Profile preview

Odevixibat versus placebo after Kasai procedure in children with biliary atresia

NL-OMON61227Phase 3Completed

Sponsor
Ipsen
Start
Jan 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in biliary atresia comparing Odevixibat with Placebo (2 arms). Primary endpoint: Time to liver transplant or death. Started Jan 2021; status: completed.

02

Drugs

odevixibat
03

Conditions

biliary atresia

Beyond the preview

Go deeper on NL-OMON61227.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON61227.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call